TELA Bio 

$2.62
7
+$0.13+5.22% 今天

統計

當日最高
-
當日最低
-
52週最高
-
52週最低
-
成交量
-
平均成交量
-
市值
71.67M
市盈率
-
股息收益率
-
股息
-

即將到來

收益

6Nov預期
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
下一個
-0.63
-0.5
-0.36
-0.23
預期每股收益
-0.40592
實際每股收益
N/A

人們還關注

此列表基於在 Stock Events 上關注 TELA 的人的關注列表。這不是投資建議。

競爭者

這個列表是基於最近市場事件的分析。這不是投資建議。

分析師評級

10$平均價格目標
最高估價為 $12。
來自過去 6 個月內的 4 個評級。這不是投資建議。
買入
75%
持有
25%
賣出
0%

關於

Health Technology
Medical Specialties
Manufacturing
Surgical and Medical Instrument Manufacturing
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Show more...
首席執行官
員工
227
國家
US
ISIN
US8723811084

上市公司